ATractiB

THE ATRACTIB TRIAL IS A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY EVALUATING THE COMBINATION OF ATEZOLIZUMAB, PACLITAXEL AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER (aTNBC), INDEPENDENTLY OF PD-L1 STATUS. THE PRIMARY ENDPOINT WAS INVESTIGATOR-ASSESSED PROGRESSION-FREE SURVIVAL (PFS) BY RECIST V.1.1.